The Chemotherapy Induced Nausea and Vomiting drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Nausea and Vomiting. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued products.
GlobalData tracks 24 drugs in development for Chemotherapy Induced Nausea and Vomiting by 21 companies/universities/institutes. The top development phase for Chemotherapy Induced Nausea and Vomiting is phase iii with six drugs in that stage. The Chemotherapy Induced Nausea and Vomiting pipeline has 24 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chemotherapy Induced Nausea and Vomiting pipeline products market are: Jiangsu Hengrui Medicine, Helsinn Healthcare and Aphios.
The key targets in the Chemotherapy Induced Nausea and Vomiting pipeline products market include 5-Hydroxytryptamine Receptor 3, Substance P Receptor, and Cannabinoid Receptor 1.
The key mechanisms of action in the Chemotherapy Induced Nausea and Vomiting pipeline product include 5-Hydroxytryptamine Receptor 3 Antagonist with nine drugs in Phase III. The Chemotherapy Induced Nausea and Vomiting pipeline products include nine routes of administration with the top ROA being Oral and one key molecule types in the Chemotherapy Induced Nausea and Vomiting pipeline products market including Small Molecule.
Chemotherapy Induced Nausea and Vomiting overview
Chemotherapy-induced nausea and vomiting (CINV) is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Other symptoms include a rapid heart rate, sweating, dizziness, and increased saliva. Risk factors include age, drug, dose, and the schedule and route of the drug’s administration.
For a complete picture of Chemotherapy Induced Nausea and Vomiting’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
